


MLN4924 protects against pulmonary fibrosis

Supplementary Table 1. Primers for quantitative real-time PCR

IL-1 β	Forward	5'-CAACCAACAAGTGATATTCTCCATG-3'	Mouse
	Reverse	5'-GATCCACACTCTCCAGCTGCA-3'	
TNF α	Forward	5'-GACCCTCACACTCAGATCAT-3'	Mouse
	Reverse	5'-TTGAAGAGAACCTGGGAGTA-3'	
iNOS	Forward	5'-CTTCAACCAGCAGTCCTAGACA-3'	Mouse
	Reverse	5'-TCCAGGTCCAGGAGACGGTA-3'	
MCP-1	Forward	5'-ACTGAAGCCAGCTCTCTCCCTC-3'	Mouse
	Reverse	5'-TTCCTTCTGGGGTCAGCACAGAC-3'	
KC	Forward	5'-AGGAATTCACCCAAAGAAC-3'	Human
	Reverse	5'-CACCACTGAGCTTCCTCCTC-3'	
IL-8	Forward	5'-ATGACTCCAAGCTGGCCGTG-3'	Human
	Reverse	5'-GGAGTATGTTATGCAGTACATCTA-3'	
CXCL5	Forward	5'-GAGAGCTGCGTTGCGTTG-3'	Human
	Reverse	5'-TTCCCTGTTCCACCGTCCA-3'	
GAPDH	Forward	5'-TGACAACTTGGTATCGTGGAAAG-3'	Human
	Reverse	5'-CAGTAGAGGCAGGGATGATGTT-3'	
	Forward	5'-GTCGTGGAGTCACTGGTGTG-3'	Mouse
	Reverse	5'-GAGCCCTTCCACAATGCCAAA-3'	



Supplementary Figure 1. MLN4924 has no significant influences on neutrophil apoptosis at early stage of lung injury. A. FACS analysis of apoptotic neutrophil (PI+annexin-V+) numbers stimulated by MLN4924 of indicated doses. Error bars represent mean \pm SD. B. Western blot analysis of neutrophil apoptosis under stimulations of MLN4924 with the indicated antibodies.